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Abstract 
Aims 
Many patients taking risperidone for the treatment of psychiatric disorders experience substantial body 
weight gain. Researchers have speculated that risperidone induces obesity by modulating central signals; 
however, the precise central mechanisms involved remain to be fully elucidated. 
Methods 
Twenty‐four C57BL/6J mice were divided into four groups: a control group; a risperidone‐treated group; a 
lorcaserin‐treated group; and a combined risperidone + lorcaserin‐treated group. The mice were received 
the corresponding treatments for 4 weeks, and their brains were collected for in situ hybridization 
analysis. A subset of C57BL/6J mice was administrated with risperidone or placebo, and brains were 
collected 60 minutes post‐treatment for determination of c‐fos activity. In addition, brains of NPY‐GFP 
mice treated with or without risperidone were collected to perform colocalization of NPY and c‐fos, as 
well as NPY and 5‐HT2c receptor using immunohistochemistry. 
Results 
There was significantly elevated c‐fos expression in the hypothalamic arcuate nucleus (Arc) of 
risperidone‐treated mice. More than 68% c‐fos‐positive neurons were NPY‐expressing neurons. 
Furthermore, in situ hybridization revealed that Arc NPY mRNA expression was significantly increased in 
the risperidone‐treated group compared with control group. Moreover, we identified that 95% 5‐HT2c 
receptors were colocalized with NPY positive neurons, and increased Arc NPY mRNA expression induced 
by risperidone was markedly reduced by cotreatment with lorcaserin, a specific 5‐HT2c receptor agonist. 
Conclusion 
Our findings provide critical insight into the mechanisms underlying antipsychotic‐induced obesity, which 
may assist the development of therapeutic strategies to address metabolic side effects of risperidone. 
Disciplines 
Medicine and Health Sciences 
Publication Details 
Wan, X., Zeng, F., Huang, X., Yang, H., Wang, L., Shi, Y., Zhang, Z. & Lin, S. (2020). Risperidone stimulates 
food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor—NPY 
pathway. CNS Neuroscience and Therapeutics, 26 (5), 558-566. 
Authors 
Xiao Wan, Fan Zeng, Xu-Feng Huang, He Yang, Lan Wang, Yan-Chuan Shi, Zhi Zhang, and Shu Lin 
This journal article is available at Research Online: https://ro.uow.edu.au/ihmri/1522 
CNS Neurosci Ther. 2019;00:1–9.    |  1wileyonlinelibrary.com/journal/cns
 
Received: 3 September 2019  |  Revised: 23 November 2019  |  Accepted: 26 November 2019
DOI: 10.1111/cns.13281  
O R I G I N A L  A R T I C L E
Risperidone stimulates food intake and induces body weight 
gain via the hypothalamic arcuate nucleus 5-HT2c receptor—
NPY pathway
Xiao-Qin Wan1  |   Fan Zeng1 |   Xu-Feng Huang2  |   He-Qin Yang1 |   Lan Wang1 |   
Yan-Chuan Shi3,4 |   Zhi-Hui Zhang1 |   Shu Lin1,3
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2019 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.
Wan and Zeng contributed equally to this work. 
1Department of Cardiology, Southwest 
Hospital, Third Military Medical University 
(Currently Army Medical University), 
Chongqing, China
2Illawarra Health and Medical Research 
Institute and School of Medicine, University 
of Wollongong, Wollongong, NSW, Australia
3Diabetes and Metabolism Division, Garvan 
Institute of Medical Research, Darlinghurst, 
Sydney, NSW, Australia
4Faculty of Medicine, St Vincent's Clinical 
School, UNSW Sydney, Sydney, NSW, 
Australia
Correspondence
Shu Lin and Zhi-Hui Zhang, No.30 
Gaotanyan, Shapingba, Chongqing, 400038, 
China.
Emails: shulin1956@126.com; xyzpj@126.
com
Funding information
Southwest Hospital Project, Grant/Award 
Number: SWH2016HWHZ-04 and PTJS11; 
National Natural Science Foundation of 
China, Grant/Award Number: 81570395
Abstract
Aims: Many patients taking risperidone for the treatment of psychiatric disorders ex-
perience substantial body weight gain. Researchers have speculated that risperidone 
induces obesity by modulating central signals; however, the precise central mecha-
nisms involved remain to be fully elucidated.
Methods: Twenty-four C57BL/6J mice were divided into four groups: a control 
group; a risperidone-treated group; a lorcaserin-treated group; and a combined risp-
eridone + lorcaserin-treated group. The mice were received the corresponding treat-
ments for 4 weeks, and their brains were collected for in situ hybridization analysis. A 
subset of C57BL/6J mice was administrated with risperidone or placebo, and brains 
were collected 60 minutes post-treatment for determination of c-fos activity. In ad-
dition, brains of NPY-GFP mice treated with or without risperidone were collected to 
perform colocalization of NPY and c-fos, as well as NPY and 5-HT2c receptor using 
immunohistochemistry.
Results: There was significantly elevated c-fos expression in the hypothalamic arcu-
ate nucleus (Arc) of risperidone-treated mice. More than 68% c-fos-positive neurons 
were NPY-expressing neurons. Furthermore, in situ hybridization revealed that Arc 
NPY mRNA expression was significantly increased in the risperidone-treated group 
compared with control group. Moreover, we identified that 95% 5-HT2c receptors 
were colocalized with NPY positive neurons, and increased Arc NPY mRNA expres-
sion induced by risperidone was markedly reduced by cotreatment with lorcaserin, a 
specific 5-HT2c receptor agonist.
Conclusion: Our findings provide critical insight into the mechanisms underlying an-
tipsychotic-induced obesity, which may assist the development of therapeutic strate-
gies to address metabolic side effects of risperidone.
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1  | INTRODUC TION
Second-generation antipsychotics (SGAs) are used to effectively 
treat a variety of psychiatric disorders, including schizophrenia, 
bipolar disorder, autism spectrum disorder (ASD), and Alzheimer's 
disease.1 Most SGAs are associated with a wide range of potential 
adverse effects such as obesity, obesity-associated dyslipidemia, and 
type 2 diabetes.2 In addition, life expectancy is reduced in patients 
with schizophrenia who have obesity-related metabolic syndrome.3
Risperidone, a benzisoxazole derivative, is one of the SGAs with 
selective antagonistic properties at 5-HT2c receptors.4 Over the 
past two decades, risperidone has been used to effectively treat a 
broad spectrum of psychiatric disorders.5 Indeed, risperidone is the 
most commonly prescribed antipsychotic medication among chil-
dren and adolescents with bipolar disorder, schizophrenia, and at-
tention-deficit/hyperactivity disorder (ADHD).6,7
Compared to first-generation antipsychotics, second-generation 
antipsychotics cause fewer extra-pyramidal problems, but they pres-
ent new challenges because they often lead to metabolic disorders. For 
example, risperidone increases food intake and induces weight gain, 
glucose intolerance, hypertriglyceridemia, and hyperprolactinemia.8-10 
Previous research has suggested that risperidone induces weight gain 
by upregulating the expression of hypothalamic histaminergic H1 re-
ceptors and neuropeptide Y (NPY).11 Central NPY signaling is known to 
play a critical role in the regulation of food intake and energy balance,12 
suggesting that preventing or reversing the increase in NPY expression 
may help reduce risperidone-induced weight gain. Several main nuclei 
in the hypothalamus are involved in the regulation of body weight and 
food intake, including the hypothalamic arcuate nuclei (Arc), dorsome-
dial hypothalamic nuclei (DMH), and lateral hypothalamic area (LHA).12 
In particular, NPY neurons in the Arc play a critical role in the control 
of energy homeostasis. The activation of NPY neurons in the Arc in-
creases appetite.13,14 These neurons project to other nearby hypo-
thalamic areas to coordinate appetite control. For instance, Arc NPY 
neurons mediate the effect of LHA neurons on feeding behavior.15 
Additional research has indicated that NPY neurons, which are abun-
dantly expressed in the DMH following exposure to a high-fat diet, 
exert their effects independently of sympathetic activity.16
In contrast to their non-obesogenic counterparts, obesogenic 
SGAs are commonly associated with potent 5-HT2c receptor an-
tagonism.17 A previous study reported that 5-HT2c receptors can 
inhibit the expression of orexigenic growth hormone secretagogue 
receptor 1a (GHSR1a) in the hypothalamus.18 GHSR1a stimulates 
food intake and fat deposition primarily via intracellular signaling 
pathways that increase orexigenic NPY and agouti-related peptide 
(AgRP) expression while suppressing anorexigenic pro-opiomelano-
cortin (POMC) signaling in the hypothalamus.19-21 GHSR1a antago-
nism reduces hypothalamic NPY expression, food intake, and body 
weight in rodents.22,23 Thus, restoring the activity of 5-HT2c recep-
tors may prevent increases in NPY expression. Lorcaserin, an FDA-
approved anti-obesity drug, is a selective 5-HT2c receptor agonist. 
Therefore, we speculated that cotreatment with lorcaserin would 
prevent or reverse risperidone-induced weight gain.
Based on these findings, we hypothesized that risperidone acts 
on the NPY system via 5-HT2c receptors in the Arc to increase food 
intake and body weight. In the present study, we investigated the ana-
tomic localization of 5-HT2c receptors on NPY neurons in the Arc and 
the role of 5-HT2c receptors in risperidone-induced metabolic impair-
ments in mice. We also aimed to determine whether combined treat-
ment with a 5-HT2c receptor agonist would restore 5-HT2c receptor 
inhibitory control over the obesogenic GHSR1a, thereby averting the 
onset of hyperplasia and weight gain due to risperidone treatment.
2  | MATERIAL S AND METHODS
2.1 | Animals
At 8 weeks of age, 24 female mice (C57BL/6J) were divided into 4 
groups: a control group (n = 6), a risperidone only group (n = 6), a lor-
caserin only group (n = 6), and a combined risperidone + lorcaserin 
group (n = 6). Food intake and body weight were measured weekly 
during the 4-week experimental period, and the mouse brains were 
collected for in situ hybridization. Another 10 C57BL/6J mice were 
divided into risperidone-treated mice (n = 5) and control mice (n = 5) 
for the detection of c-Fos activity. In addition, 12 transgenic mice 
expressing GFP at NPY neurons (NPY-GFP) were purchased from 
Jackson Laboratory were collected brains for double labeling immu-
nohistochemistry (NPY/c-Fos and NPY/5-HT2c receptors).
2.2 | Ethics and animal care
All experimental animal protocols were approved by the Third 
Military Medical University Animal Care Committee, in accordance 
with the National Institutes of Health Guide for the Care and Use 
of Laboratory Animals (NIH publication number: 8023). The 34 
C57BL/6J mice and 12 NPY-GFP mice were housed in temperature-
controlled (23 ± 2°C) and light-controlled (12:12-hours light-dark 
cycle, lights on at 07:00 hours) animal quarters. Mice were provided 
ad libitum access to water and a standard chow diet.
2.3 | Determining changes in food intake and body 
weight in response to risperidone treatment
At 8 weeks of age, 24 C57BL/6J mice were divided into four treat-
ment groups. After acclimatization to the experimental condi-
tions, treatments were administered at the same time every day 
for 4 weeks. One group of mice was intraperitoneally injected with 
risperidone (2 mg/kg), while the control group was treated with 
saline. One group of mice was intraperitoneally injected with risp-
eridone + lorcaserin (10 mg/kg), and one group of mice was intra-
peritoneally injected with lorcaserin only. Drug dosages were based 
on those used in previous rodent studies.24-26 Body weight and food 
intake were measured weekly during the treatment period. Food 
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intake was determined by calculating the difference between the 
given and remaining amounts of food after 24 hours. After the last 
experiments, brain tissue was collected for in situ hybridization and 
stored at −80°C until the assay.
2.4 | Immunoreactivity for c-Fos in the Arc, 
DMH, and LHA
We examined c-Fos immunoreactivity in the brains of C57BL/6J 
mice intraperitoneally injected with risperidone (2 mg/kg) (n = 5) or 
saline (n = 5) 60 minutes after treatment. To detect c-Fos expression 
in the hypothalamus, mice were anesthetized and perfused with sa-
line followed by 4% paraformaldehyde via a cannula inserted into the 
left ventricle. After perfusion, the brains were immediately removed, 
kept in 4% paraformaldehyde, immersed in 30% sucrose, and stored 
at −80°C until use. Coronal brain sections (thickness: 30 µm) were 
obtained using a microtome (Menzel-Glaser), following which c-Fos 
expression was detected as previously described.15 The primary an-
tibody (Cell Signaling Technology) was diluted at 1:400 in antibody 
buffer diluent. The brain sections were then incubated with second-
ary antibody against c-Fos (Alexa Fluor® 594 goat anti-rabbit IgG, 
A11037, Life Technologies) for 3 hours. A Nikon orthotopic micro-
scope was used to visualize red c-Fos staining. Data were expressed 
as the average number of stained nuclei within the brain nuclei of 
interest and quantified using ImageJ software (NIH). To ensure con-
sistency in the analysis of cell counts between the groups, sections 
through the Arc, DMH, and LHA of risperidone-treated and control 
animals were examined as previously described.27
2.5 | Double labeling of NPY neurons and c-Fos 
immunoreactivity in the Arc of NPY-GFP mice
Eight NPY-GFP transgenic mice aged 10 weeks were purchased 
from Jackson Laboratory. The NPY-GFP mice were treated with ris-
peridone (n = 4) (2 mg/kg) or saline (n = 4) as previously mentioned. 
Sixty minutes later, mice were sacrificed, and their brains were im-
mediately removed and placed on dry ice. The brain samples were 
then incubated with the primary antibody (rabbit-anti-mouse c-Fos; 
1:400) (Cell Signaling Technology), followed by a secondary antibody 
against c-Fos to visualize red fluorescent staining (Alexa Fluor® 594 
goat anti-rabbit IgG, A11037, Life Technologies), and a Nikon ortho-
topic microscope was used to visualize green fluorescent-stained 
NPY neurons overlapping red c-Fos-stained neurons.
2.6 | Double labeling of NPY neurons and 5-HT2c 
receptor immunoreactivity in the Arc of NPY-
GFP mice
The remaining 4 NPY-GFP mice were used to detect double labeling 
of NPY neurons and 5-HT2c receptor immunoreactivity in the Arc. 
NPY-GFP mice were sacrificed, following which their brains were re-
moved and placed on dry ice. The brains were then incubated with 
the primary antibody (rabbit-anti-mouse 5-HT2c receptor; 1:300) 
(Cell Signaling Technology), followed by a secondary antibody against 
5-HT2c receptor to visualize red fluorescent staining (Alexa Fluor® 
594 goat anti-rabbit IgG, A11037, Life Technologies). A Nikon ortho-
topic microscope was used to visualize green fluorescent-stained 
NPY neurons overlapping red 5-HT2c receptor-stained neurons.
2.7 | In situ hybridization (ISH) using 
RNAscope technology
Brain samples collected from the four groups were used for ISH. Fresh 
brain tissue was cryosectioned at 20 µm and stored at −80°C. Transcript 
detection was performed using the commercially available RNAscope 
brown reagent kit (Advanced Cell Diagnostics). ISH was performed in 
accordance with the manufacturer's instructions for fixed-frozen tis-
sue. Detection experiments were performed in a hybridization oven 
(HybEZ™, ACD) with RNAscope Probe-mm-NPY (ACD 313321). Ppib 
probe (ACD 313911), a mouse housekeeping gene, was used as a posi-
tive control, while a bacterial dapB probe (ACD 310043) was used as 
a negative control. Each set of probes contained a tag that enabled 
visualization of the target transcript in brown. To compare differences 
in expression among the 4 groups, we quantified the integral optical 
density (IOD) of positive NPY staining using ImageJ, normalized by 
the stained area. The mean intensities from three random areas of the 
same size in the target areas were measured for each probe.
2.8 | Statistical analyses
To determine the differences in calories intake, body weight and Arc 
NPY mRNA expression among four groups at the end of experiment, 
ordinary one-way analysis of variance (ANOVA) with Tukey's post 
hoc test was used. To determine the difference between control and 
risperidone treatment group at various brain regions (Arc, DMH, and 
LHA), unpaired t test with two-tailed P value was used (GraphPad 
Prism 5, version 5.0a; GraphPad Software). For all statistical analy-
ses, the values were expressed as means ± SEM P values < .05 were 
considered statistically significant.
3  | RESULTS
3.1 | Risperidone stimulates food intake and 
increases body weight in mice
During the 4-week experiment, food intake and body weight 
increased over time in all groups. At the end of experiment, sig-
nificant differences in calorie intake were observed between 
the risperidone-treated groups and control groups (risperidone 
vs control, 10 ± 0.209 vs 8.6 ± 0.363 kcal, F value (3,12) = 19.01, 
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P = .018) (Figure 1, Table 1). Also, there was significant difference 
in body weight between these two groups (risperidone vs control, 
20.6 ± 0.216 vs 19.6 ± 0.231 g; F value (3,9) = 15.39, P = .026) 
(Figure 2, Table 1).
3.2 | Risperidone activates c-Fos expression in the 
hypothalamic Arc, DMH, and LHA
We examined c-Fos expression to determine which brain regions were 
activated in response to risperidone treatment. The numbers of c-
Fos-labeled neurons in risperidone-treated mice vs control mice were 
73.6 ± 4.02 vs 43.6 ± 3.572 in the Arc (Figure 3A and B, P = .001); 
115 ± 6.066 vs 42 ± 2.775 in the DMH (Figure 3C and D, P < .001); 
and 70.8 ± 5.389 vs 35 ± 4.946 in the LHA (Figure 3E and F, P = .001).
3.3 | NPY neurons colocalize with c-Fos-positive 
neurons in the Arc following risperidone treatment
To confirm whether c-Fos-positive neurons exhibit a relationship 
with NPY neurons, we examined c-Fos immunoreactivity in NPY-
GFP mice. Sixty minutes after risperidone or saline treatment, we 
observed that 68% of c-Fos-positive neurons overlapped with NPY-
GFP neurons in the Arc in the risperidone group, while the overlap-
ping ratio in the control group was only 21% (Figure 4).
3.4 | Risperidone increases the expression of NPY 
mRNA in the Arc
Since Arc neurons are activated by risperidone, we examined NPY 
mRNA expression in Arc neurons via ISH. The NPY mRNA expres-
sion in the Arc was significantly higher in the risperidone-treated 
group than in the control group (Figure 5).
3.5 | 5-HT2c receptors colocalize with NPY neurons 
in the Arc of NPY-GFP mice
To determine whether 5-HT2c receptors colocalize with NPY neu-
rons in the Arc, we examined 5-HT2c immunoreactivity in NPY-GFP 
mice via double-receptor labeling experiments. Our findings indi-
cated that 95% of 5-HT2c receptor overlapped with NPY-GFP neu-
rons in the Arc (Figure 6).
3.6 | Lorcaserin counteracts risperidone-induced 
increases in NPY mRNA expression in the Arc
Treatment with the selective 5-HT2c receptor agonist lorcaserin led 
to weight loss (lorcaserin vs control, 18.5 ± 0.173 vs 19.6 ± 0.231 g, 
F value (3,9) = 15.39, P = .019) and alleviated weight gain caused 
by risperidone (lorcaserin + risperidone vs control, 19.6 ± 0.265 vs 
19.6 ± 0.231 g, F value (3,9) = 15.39, P = .865) (Figure 2). Therefore, 
we examined levels of NPY mRNA expression in Arc neurons in the 
lorcaserin + risperidone group and the lorcaserin only group. The Arc 
NPY mRNA expression was lower in the lorcaserin only group than in 
the control group (lorcaserin vs control, 13.4 ± 0.927 vs 22.4 ± 1.749, 
F value (3,16) = 18.16, P = .014). However, no obvious differences in 
NPY mRNA expression were observed between the lorcaserin + ris-
peridone group and the control group lorcaserin + risperidone vs 
control, 22.6 ± 1.536 vs 22.4 ± 1.749, F value (3,16) = 18.16, P = .9) 
(Figure 5, Table 1).
4  | DISCUSSION
In the current study, we investigated the role of 5-HT2c receptors 
in risperidone-induced metabolic impairments, as well as the ability 
of a 5-HT2c receptor agonist to attenuate these impairments. Our 
findings indicated that mice exhibited significant increases in body 
weight and daily food intake after 4 weeks of risperidone treatment. 
In the risperidone group, more than half of neurons expressing the 
c-Fos gene colocalized with NPY, and almost all neurons expressing 
5-HT2c receptors colocalized with NPY. In addition, treatment with 
the 5-HT2c receptor agonist lorcaserin significantly decreased the 
expression of NPY mRNA in the Arc. Such findings suggest that ris-
peridone induces hyperphagia and obesity via the 5-HT2c receptor-
NPY pathway in the Arc.
Risperidone stimulates food intake and increases body weight by 
affecting signals passing through the “hypothalamic feeding center”.28 
Interactions between hypothalamic neural networks and peripheral 
positive energy balance rely on neuronal pathways that are involved in 
autonomic outflow from the brain. NPY in the Arc is a main central food 
stimulator responsible for restoring energy balance. Furthermore, NPY 
neurons from the Arc that project to the LHA play a major role in the 
regulation of food intake,29 while those that project to the DMH aid in 
reducing energy expenditure.15 Previous research has suggested that 
Arc NPY signaling is the most potent stimulator of food intake, exerting 
F I G U R E  1   Daily food (calorie) after 4-wk treatment. Results are 
shown as mean ± SEM of 4-6 mice per group. *P < .05; **P < .01; 
***P < .001. Risp: risperidone-treated group; Lor: lorcaserin-treated 
group; Risp + Lor: risperidone + lorcaserin-treated group; C: control 
group
     |  5WAN et Al.
its effects by binding to Y1 receptors in the paraventricular nucleus 
(PVN).14 In the current study, risperidone treatment significantly in-
creased c-Fos expression in the Arc, indicating that risperidone initially 
activates neurons concentrated within this nucleus. In addition, we ob-
served that 68% of c-Fos-positive neurons overlapped with NPY-GFP 
neurons in the Arc in NPY-GFP mice, suggesting that risperidone acti-
vates NPY neurons in the Arc. In order to determine whether Arc NPY 
neurons express 5-HT2c receptors, we performed double-labeling 
experiments to examine 5-HT2c immunoreactivity in NPY-GFP mice. 
To the best of our knowledge, the present study is the first to report 
that 95% of 5-HT2c receptors overlapped with NPY-GFP neurons in 
the Arc. Risperidone is a potent 5-HT2c receptor antagonist, and pre-
vious studies have demonstrated that obesogenic antipsychotic drugs 
reduce 5-HT2c receptor inhibition of GSHR1a.17 Therefore, our results 
indicate that risperidone may selectively stimulate NPY expression in 
the Arc by reducing 5-HT2c receptor activity, thereby increasing food 
intake.
Research has revealed that NPY neurons in the Arc project to 
downstream LHA neurons via Y1 receptors, which play a crucial 
role in modulating feeding behavior.30 In the present study, abun-
dant c-Fos expression was observed in the LHA 60 minutes after 
risperidone treatment. Such increases were likely responsible for 
the observed increases in food intake among risperidone-treated 
animals, as previous studies have indicated that orexin and mela-
nin-concentrating hormone (MCH) are also abundantly expressed 
in the LHA. Indeed, both orexin and MCH stimulate feeding in rats 
when injected intracerebroventricularly (ICV).31,32
Weight gain is caused by either increased food intake, decreased 
energy expenditure, or both. Recent studies have begun to decipher 
the pathways responsible for energy homeostasis, and several groups 
are actively engaged in the development of pharmacological agents 
targeting these pathways. Such findings are in accordance with the 
observed increases in c-Fos immunoreactivity in the DMH 60 min-
utes after risperidone treatment. Arc neurons send extensive projec-
tions to the DMH. These neuronal projections are important routes 
 Control Risperidone Risperidone + Lorcaserin Lorcaserin
Body weight 
(g)
19.6 ± 0.231* 20.6 ± 0.216 19.6 ± 0.265** 18.5 ± 0.173***
Calorie intake 
(kcal)
8.6 ± 0.363* 10 ± 0.209 8.7 ± 0.183** 7.7 ± 0.107***
c-Fos in the 
Arc
43.6 ± 3.572#  73.6 ± 4.02 / /
c-Fos in the 
DMH
42 ± 2.775#  115 ± 6.066 / /
c-Fos in the 
LHA
35 ± 4.946#  70.8 ± 5.389 / /
mRNA in the 
Arc
22.4 ± 1.749* 32.2 ± 2.634 22.6 ± 1.536** 13.4 ± 0.927***
Note: Data are means ± SEM, n = 4-6 for each group. The differences were determined by either 
one-way ANOVA with Tukey post hoc test for body weight and calorie intake or unpair t test for 
c-fos analysis.
*P < .05 vs risperidone or lorcaserin. 
**P < .05 vs risperidone or lorcaserin. 
***P < .05 vs risperidone. 
#P < .05 vs risperidone. 
TA B L E  1   The calorie intake, body 
weight, and the Arc mRNA expressions 
after 4-wk treatment and the c-fos 
expression in the brain area of Arc, DMH, 
and LHA after 60-min treatment
F I G U R E  2   Body weight after treatment. A, The body weight 
measured weekly during treatment. B, Body weight after 
treatment for 4 wks. Results are shown as mean ± SEM of 4-6 
mice per group,*P < .05; **P < .01; ***P < .001. Risp: risperidone-
treated group; Lor: lorcaserin-treated group; Risp + Lor: 
risperidone + lorcaserin-treated group; C: control group
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for leptin, insulin, and ghrelin in the hypothalamus.33 Researchers 
have speculated that Arc NPY neurons projecting to the DMH con-
trol energy balance by stimulating food intake and inhibiting heat 
generation, especially in the case of energy deficiency.34 It is well 
known that a set of neurons distributed in the DMH is responsible 
for these functions (eg, cocaine- and amphetamine-regulated tran-
script (CART) neurons and cholinergic neurons). Further studies are 
required to identify the central mechanisms underlying changes in 
F I G U R E  3   The expression of c-Fos was increased in the Arc, DMH, and LHA after risperidone treatment for 60 min. The expression 
of c-fos of C57BL/6J mice treated with saline in the Arc (A), DMH (C) and LHA (E). The expression of c-Fos of C57BL/6J mice treated with 
risperidone in the Arc (B), DMH (D), and LHA (F). G, H, I results are shown as means ± SEM of 5 mice per group. ***P < .001, control group vs 
risperidone-treated group. Arc: arcuate hypothalamic nucleus; DMH: dorsomedial hypothalamic nuclei, LHA: lateral hypothalamic area, 3V: 
the third cerebral ventricle, f: fornix, Scale bar = 100 µm
(A) (B)
(G)
(H)
(I)
(C) (D)
(E) (F)
F I G U R E  4   Fluorescent immunohistochemical detection of c-Fos and GFP-NPY neurons coexpressed in the hypothalamic arcuate nucleus 
at 60 min after saline (A-C) or risperidone (D-F) treatment. A and D, Green staining shows NPY neurons expressing GFP; (B, E): red staining 
shows c-Fos-positive neurons. C and F, Yellow staining indicating that the neurons express both c-fos and NPY; C'&F' is higher magnification 
of the boxed area in C&F. Scale bars in A-F is 80 μm and in C'&F' is 25 μm
(A) (B) (C)
(D) (E) (F)
(C′)
(F′)
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F I G U R E  5   Upregulated NPY 
mRNA expression in the Arc caused by 
risperidone treatment and downregulated 
NPY mRNA expression in the Arc after 
treated by lorcaserin; (A) NPY mRNA 
expression in the Arc of risperidone-
treated mouse; (B) NPY mRNA 
expression in the Arc of control mouse; 
(C) NPY mRNA expression in the Arc of 
risperidone + lorcaserin-treated mouse; 
(D) NPY mRNA expression in the Arc 
of lorcaserin-treated mouse; (E) data 
are means ± SEM of 6 mice per group. 
*P < .05, **P < .01, ***P < .001, control 
group vs risperidone-treated group. 
3V: the third ventricle; Arc: arcuate 
hypothalamic nucleus; Risp: risperidone-
treated group; Lor: lorcaserin-treated 
group; Risp + Lor: risperidone + lorcaserin-
treated group; C: control group; Scale 
bar = 100 µm
(A) (B)
(C)
(E)
(D)
F I G U R E  6   Fluorescent 
immunohistochemical detection of 5HT2c 
receptor and NPY neurons coexpressed 
in the Arc. A, Green staining shows NPY 
neurons expressing GFP; (B): red staining 
shows the 5HT2c receptors; (C): yellow 
staining indicating that the neurons 
express both 5HT2c receptors and NPY; 
(D) is higher magnification of the boxed 
area in D’. Scale bars in A, B, and C is 
80 μm and in D is 25 μm
(A) (B)
(C) (D)
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signaling between Arc NPY neurons and the DMH during risperidone 
treatment. Such studies may aid in the development of better anti-
psychotics with fewer side effects.
Notably, our findings indicated that treatment with lorca-
serin attenuated risperidone-induced increases in NPY mRNA 
expression in the mouse Arc. Lorcaserin, an FDA-approved an-
ti-obesity drug, is a selective 5-HT2c receptor agonist that also 
inhibits ghrelin signaling.18 A previous randomized, double-blind, 
placebo-controlled clinical trial involving 2,200 individuals with 
excessive weight or obesity indicated that lorcaserin treatment 
was associated with 5%-10% weight loss over a follow-up period 
of 1 year.35 Therefore, cotreatment with lorcaserin may restore 
5-HT2c receptor activity and prevent the initial disruption of 
GHSR1a-induced appetite signaling caused by risperidone, which 
may in turn avert the onset of hyperphagia and weight gain. Huang 
et al reported that treatment with a GHSR1a antagonist inhibits 
GSHR1a signaling and prevents olanzapine-induced hyperpha-
gia in rats.23,36 However, widespread GHSR1a blockade may not 
be ideal for combating SGA-induced obesity given the beneficial 
effects of ghrelin on cognitive function.37 However, restoring 
normal hypothalamic GHSR1a activity by targeting the 5-HT2c 
receptor-GHSR1a dimer may directly address the mechanisms 
underlying olanzapine-induced obesity. In addition, accumulating 
evidence has demonstrated that 5-HT2c agonists exhibit procog-
nitive effects,38,39 suggesting that the use of 5-HT2c receptor ag-
onists can combat both obesity and psychiatric symptoms.
Our present study identifies a novel neuronal 5-HT2c re-
ceptor-NPY pathway via which antipsychotic medication risper-
idone increases energy intake and promotes body weight gain, 
and cotreatment with lorcaserin attenuates these side effects. 
This study highlights the importance of 5-HT2c receptors in Arc 
NPY neurons in mediating risperidone's action on weight gain. It 
is worthwhile noting that an earlier study has shown that 5-HT2c 
receptors in POMC neurons only is sufficient to mediate effects of 
serotoninergic compounds on food intake40; therefore, it is possible 
that the 5-HT2c receptors in other neurons, for instance, Arc POMC 
neurons, may also play a role in risperidone-induced body weight 
gain. Further studies are warranted to identify the involvement of 
5-HT2c receptors in other brain regions. Indeed, Pérez-Maceira 
and colleagues demonstrate that 5-HT2c receptor agonists MK212 
does not alter hypothalamic AgRP mRNA expression in rainbow 
trout41; therefore, 5-HT2c receptor in AGRP neurons may not play a 
main role in the risperidone-induced weight gain. In addition, risper-
idone is antagonism of dopamine D2 receptors, which could lead 
to reduced voluntary activity and energy expenditure42,43; there-
fore, the blockade of dopamine D2 receptors by risperidone may 
also contribute to risperidone-induced weight gain. Similarly, there 
is evidence showing that risperidone significantly elevates mRNA 
expression of hypothalamic histamine H1 receptor (H1R), leading to 
hyperphagia and body weight gain in rats,11 which suggests an in-
volvement of hypothalamic H1R in risperidone-induced hyperpha-
gia and obesity. Thus, it becomes evident that risperidone causes 
weight gain and obesity via complex mechanisms involving multiple 
neuronal pathways. Together, our present study unravels a key 
novel neural circuitry via which risperidone induces its metabolic 
side effects. Our findings will provide important evidence for the 
development of novel therapeutics to treat the SGAs-associated 
metabolic disorders.
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